Speaker 02.05.26
02.05
Capital 4 Growth Dinner | DxPx Conference EU 2026
Leonardo Royal Hotel Munich
Germany
Steven Green advises emerging growth companies in the life sciences and technology industries across the full spectrum of business and legal issues throughout their corporate life cycles. He serves as a trusted advisor and guides his clients through company formation, early-stage financings, employment and executive compensation matters, capital raisings, joint ventures, mergers and acquisitions, and initial public offerings. Steven also represents venture capital firms and strategic investors in structuring and executing investments in cutting-edge companies across the innovation economy.
Steven’s transactional work spans a wide range of industries and deal structures, with a focus on high-growth sectors, such as biotechnology, pharmaceuticals, medical devices, diagnostics, digital health, software and enterprise technologies. His practical, business-oriented approach enables clients to navigate evolving legal and regulatory frameworks while advancing their strategic objectives.
View More
Prior to joining Pillsbury, Steven was a partner at the Silicon Valley office of an international law firm.
Representative Experience
Prior to and since joining Pillsbury, Steven’s notable representations include:
- Represented ACELYRIN in connection with its $300 million Series C financing.
- Represented Sword Health in connection with its $163 million Series D financing and $85 million Series C financing.
- Represented Wellth in connection with its $36 million Series C financing and $20 million Series B financing.
View More
- Representative VC Financings Experience
- Represented Nuvig Therapeutics in connection with its $47 million Series A financing.
- Represented Medipost in connection with its CAD $90 million joint venture agreement with OmniaBio.
- Represented Vesalius Therapeutics in connection with its strategic alliance agreement with GSK, in which Vesalius will receive $80 million upfront.
- Represented Questa Capital in connection with its investment in Vynca’s $30 million funding round.
- Represented Myrobalan Therapeutics in connection with its $33 million Series A financing.
- Represented InpharmD in connection with its $6 million Series Seed financing.
- Representative Mergers & Acquisitions Experience
- Represented AbsCi in connection with its acquisition of Totient.
- Represented Advanced Biologics in connection with its merger with Isto Biologics.
- Represented Mablink Bioscience in connection with its sale to Eli Lilly and Company.
Education
-
J.D., University of Chicago Law School, 2010
B.S., University of Oregon, 2007
with honors
Admissions
-
California